The expression of CDX2 is a sensitive and specific marker for the secondary type, arising from anorectal or colonic adenocarcinoma [7], but CDX2 fails to distinguish primary disease from EMPD secondary to urothelial or prostatic malignancy [8]. This evidence concerns the gene CDX2 and colon adenocarcinoma.